clinicaladvisor.com

Residual anxiety after venlafaxine treatment associated with depressive relapse

Depression relapse. Venlafaxine was superior to lithium in reducing symptoms of both bipolar II, depression, and anxiety. According to the results of a recent study published in the Journal of ...
Seeking Alpha

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)

PITTSBURGH and TOKYO, Oct. 9, 2024 /PRNewswire/ -- Viatris Inc. (VTRS) (NASDAQ: VTRS), a global healthcare company, today announced positive top-line results of its Phase 3 study (B2411367) in Japan ...

Antidepressant Side Effects Vary Widely by Drug, Study Finds

A new large-scale analysis found that the short-term cardiovascular and metabolic side effects of antidepressants vary widely ...
Nasdaq

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder

Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan As previously announced, our Phase 3 ...
Nasdaq

Viatris Submits SNDA In Japan For Effexor To Treat Generalized Anxiety Disorder

(RTTNews) - Viatris Inc. (VTRS), a healthcare company, Monday said it has submitted Supplemental New Drug Application to Japan's Ministry of Health, Labor and Welfare (MHLW) for Effexor to treat ...
Morningstar

Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder

Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan "The filing of our supplemental New Drug ...